Emergent Biosolutions
EBS
184 hedge funds and large institutions have $1.02B invested in Emergent Biosolutions in 2015 Q2 according to their latest regulatory filings, with 31 funds opening new positions, 73 increasing their positions, 63 reducing their positions, and 19 closing their positions.
80% more call options, than puts
Call options by funds: $594K | Put options by funds: $330K
63% more first-time investments, than exits
New positions opened: 31 | Existing positions closed: 19
17% more capital invested
Capital invested by funds: $875M → $1.02B (+$150M)
16% more repeat investments, than reductions
Existing positions increased: 73 | Existing positions reduced: 63
7% more funds holding
Funds holding: 172 → 184 (+12)
1.06% more ownership
Funds ownership: 80.77% → 81.84% (+1.1%)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AL
AJO LP
Philadelphia,
Pennsylvania
|
+$12M |
| 2 |
EAM
Eagle Asset Management
St Petersburg,
Florida
|
+$7.02M |
| 3 |
ACMM
Arbor Capital Management (Minnesota)
Minneapolis,
Minnesota
|
+$4.38M |
| 4 |
Prudential Financial
Newark,
New Jersey
|
+$4.01M |
| 5 |
Goldman Sachs
New York
|
+$3.86M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACA
Avoro Capital Advisors
New York
|
-$9.51M |
| 2 |
Millennium Management
New York
|
-$6.05M |
| 3 |
Bank of New York Mellon
New York
|
-$4.97M |
| 4 |
NI
Numeric Investors
Boston,
Massachusetts
|
-$4.81M |
| 5 |
TC
TFS Capital
West Chester,
Pennsylvania
|
-$4.31M |
EBS Hedge Fund Activity: Q2 2015 in Review
184 of the 3,712 institutional investors tracked by Wall St. Rank reported a position in Emergent Biosolutions (EBS) for Q2 2015, worth a combined $1.02B — up 17% from $875M a quarter earlier.
Buyers outnumbered sellers: 31 funds opened new EBS positions and 19 closed out — a net gain of 12 holders — while 73 added to existing stakes and 63 trimmed.
The largest buyer was AJO LP, opening a new position worth an estimated $12M. The largest seller was Avoro Capital Advisors, exiting entirely with an estimated $9.51M sold.
- 184 institutional investors held Emergent Biosolutions (EBS) as of Q2 2015, up from 172 in Q1 2015.
- Funds reported $1.02B of Emergent Biosolutions stock for Q2 2015, up 17% quarter-over-quarter.
- 31 funds opened new Emergent Biosolutions positions in Q2 2015 and 19 closed out, a net change of +12 holders.
- The largest Emergent Biosolutions buyer in Q2 2015 was AJO LP, an estimated $12M added.
- The largest Emergent Biosolutions seller in Q2 2015 was Avoro Capital Advisors, an estimated $9.51M sold.
Based on aggregated 13F filings for Q2 2015.